|
|
|
|
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
EBSCO_ocn952337061 |
| 003 |
OCoLC |
| 005 |
20231017213018.0 |
| 006 |
m o d |
| 007 |
cr ||||||||||| |
| 008 |
160201s2016 nyu ob 001 0 eng |
| 010 |
|
|
|a 2020676217
|
| 040 |
|
|
|a DLC
|b eng
|e rda
|c DLC
|d N$T
|d EBLCP
|d YDX
|d OCLCF
|d AGLDB
|d SNK
|d DKU
|d IGB
|d D6H
|d VTS
|d G3B
|d S8J
|d S9I
|d STF
|d OCLCO
|d OCL
|d OCLCO
|d OCLCQ
|d OCLCA
|d OCL
|d OCLCA
|d OCLCO
|
| 019 |
|
|
|a 961201701
|
| 020 |
|
|
|a 9781634847704
|q ebook
|
| 020 |
|
|
|a 1634847709
|
| 020 |
|
|
|z 1634846680
|
| 020 |
|
|
|z 9781634846684
|
| 029 |
1 |
|
|a AU@
|b 000062420333
|
| 035 |
|
|
|a (OCoLC)952337061
|z (OCoLC)961201701
|
| 050 |
0 |
0 |
|a RC271.C5
|
| 060 |
|
4 |
|a QZ 267
|
| 072 |
|
7 |
|a HEA
|x 039000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 014000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 022000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 112000
|2 bisacsh
|
| 072 |
|
7 |
|a MED
|x 045000
|2 bisacsh
|
| 082 |
0 |
0 |
|a 616.99/4061
|2 23
|
| 049 |
|
|
|a UAMI
|
| 100 |
1 |
|
|a Lacroix, Marc,
|d 1963-
|e author.
|
| 245 |
1 |
0 |
|a Targeted therapies in cancer :
|b an update /
|c Marc Lacroix.
|
| 264 |
|
1 |
|a New York :
|b Nova Biomedical,
|c [2016]
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Cancer etiology, diagnosis and treatments
|
| 504 |
|
|
|a Includes bibliographical references and index.
|
| 588 |
|
|
|a Description based on print version record.
|
| 505 |
0 |
|
|a TARGETED THERAPIES IN CANCER AN UPDATE ; TARGETED THERAPIES IN CANCER AN UPDATE ; Contents ; Preface ; Abbreviations ; Chapter 1 Innovation in the Biopharmaceutical Pipeline ; Abstract ; Introduction ; Drug Discovery and Development Process ; Discovery and Preclinical Testing ; Clinical Testing in Human Subjects ; Regulatory Review and Approval ; Post-Approval Research and Monitoring ; References ; Chapter 2 The Diversity of Targeted Cancer Drugs Recently Approved by the FDA ; Abstract ; Introduction ; 1. Tyrosine Kinase (TK) Inhibitors (TKIs)
|
| 505 |
8 |
|
|a 2. Serine/Threonine Kinase Inhibitors (STKIs) 3. Dual Specificity Kinase Inhibitors (DSKIs) ; 4. Lipid Kinase Inhibitors (LKIs) ; 5. Poly ADP Ribose Polymerase (PARP) Inhibitors (PARPIs) ; 6. Monoclonal Antibodies (mAbs) ; 7. Microtubule Targeting Agents (MTAs) ; 8. Histone Deacetylase (HDAC) Inhibitors ; 9. Proteasome Inhibitors ; 10. Antimetabolites; 11. Immunomodulatory Agents (iMiDs) ; 12. DNA Methyltransferase Inhibitors ; 13. Hedgehog Pathway Inhibitor ; 14. Enzymes ; 15. Hormone (Androgen Deprivation) Therapy ; 16. Decoy Vascular Endothelial Growth Factor Receptor
|
| 505 |
8 |
|
|a 17. Protein Translation Inhibitor 18. Somatostatin (SST) Analogue ; 19. Autologous Cellular Immunotherapy (Vaccine) ; 20. Oncolytic Virus ; 21. Alkylating Agent ; 22. Radiopharmaceutical Compound ; References ; Chapter 3 Chronological List of Targeted Cancer Drugs Approved by the FDA ; Abstract ; Introduction ; Reference ; Chapter 4 Targeted Therapies: Detailed Description ; Abstract ; Introduction ; Rituximab (Rituxan®) ; Trastuzumab (Herceptin®) ; Imatinib (Gleevec® -US- or Glivec® -EU-) ; Alemtuzumab (Campath®) ; Ibritumomab Tiuxetan (Zevalin®) ; Gefitinib (Iressa®)
|
| 505 |
8 |
|
|a Tositumomab (Bexxar®) Azacitidine (Arzerra®) ; Pemetrexed (Alimta®) ; Cetuximab (Erbitux®) ; Bevacizumab (Avastin®) ; Erlotinib (Tarceva®) ; Nelarabine (Arranon®) ; Sorafenib (Nexavar®) ; Pegaspargase (Oncospar®) ; Lenalidomide (Revlimid®) ; Sunitinib (Sutent®) ; Dasatinib (Sprycel®) ; Panitumumab (Vectibix®) ; Vorinostat (Zolinza®) ; Bortezomib (Velcade®) ; Decitabine (Dacogen®) ; Lapatinib (Tykerb®) ; Temsirolimus (Torisel®) ; Ixabepilone (Ixempra®) ; Nilotinib (Tasigna®) ; Degarelix (Firmagon®) ; Everolimus (Afinitor®) ; Pralatrexate (Folotyn®) ; Pazopanib (Votrient®)
|
| 505 |
8 |
|
|a Ofatumumab (Arzerra®) Romidepsin (Istodax®) ; Cabazitaxel (Jevtana®) ; Sipuleucel-T (Provenge®) ; Eribulin Mesylate (Halaven®) ; Denosumab (Xgeva®) ; Ipilimumab (Yervoy®) ; Vandetanib (Caprelsa®) ; Abiraterone Acetate (Zytiga®) ; Vemurafenib (Zelboraf®) ; Brentuximab Vedotin (Adcetris®) ; Crizotinib (Xalkori®) ; Ruxolitinib (Jakafi®) ; Asparaginase Erwinia Chrysanthemi (Erwinaze®) ; Axitinib (Inlyta®) ; Vismodegib (Erivedge®) ; Pertuzumab (Perjeta®) ; Carfilzomib (Kyprolis®) ; Ziv-Aflibercept (Zaltrap®) ; Enzalutamide (Xtandi®) ; Bosutinib (Bosulif®) ; Regorafenib (Stivarga®)
|
| 590 |
|
|
|a eBooks on EBSCOhost
|b EBSCO eBook Subscription Academic Collection - Worldwide
|
| 650 |
|
0 |
|a Cancer
|x Chemotherapy.
|
| 650 |
|
0 |
|a Precision medicine.
|
| 650 |
|
0 |
|a Cancer
|x Treatment.
|
| 650 |
|
2 |
|a Neoplasms
|x drug therapy
|
| 650 |
|
2 |
|a Precision Medicine
|
| 650 |
|
6 |
|a Cancer
|x Chimiothérapie.
|
| 650 |
|
6 |
|a Médecine de précision.
|
| 650 |
|
6 |
|a Cancer
|x Traitement.
|
| 650 |
|
7 |
|a HEALTH & FITNESS / Diseases / General
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Clinical Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Diseases
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Evidence-Based Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a MEDICAL / Internal Medicine
|2 bisacsh
|
| 650 |
|
7 |
|a Cancer
|x Treatment
|2 fast
|
| 650 |
|
7 |
|a Cancer
|x Chemotherapy
|2 fast
|
| 650 |
|
7 |
|a Precision medicine
|2 fast
|
| 776 |
0 |
8 |
|i Print version:
|t Targeted therapies in cancer
|d New York : Nova Biomedical, [2016]
|z 9781634846684
|w (DLC) 2016932180
|
| 830 |
|
0 |
|a Cancer etiology, diagnosis, and treatments.
|
| 856 |
4 |
0 |
|u https://ebsco.uam.elogim.com/login.aspx?direct=true&scope=site&db=nlebk&AN=1258722
|z Texto completo
|
| 938 |
|
|
|a YBP Library Services
|b YANK
|n 12882109
|
| 938 |
|
|
|a EBSCOhost
|b EBSC
|n 1258722
|
| 938 |
|
|
|a ProQuest Ebook Central
|b EBLB
|n EBL4591497
|
| 994 |
|
|
|a 92
|b IZTAP
|
